Journal of Applied Physiology Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 95: 2278-2284, 2003. First published August 1, 2003; doi:10.1152/japplphysiol.00266.2003
8750-7587/03 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
95/6/2278    most recent
00266.2003v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moldobaeva, A.
Right arrow Articles by Wagner, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moldobaeva, A.
Right arrow Articles by Wagner, E. M.

Angiotensin-converting enzyme activity in ovine bronchial vasculature

Aigul Moldobaeva and Elizabeth M. Wagner

Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21224

Submitted 13 March 2003 ; accepted in final form 30 July 2003

Angiotensin-converting enzyme (ACE) plays a major role in the metabolism of bradykinin, angiotensin, and neuropeptides, which are all implicated in inflammatory airway diseases. The activity of ACE, which is localized on the luminal surface of endothelial cells (EC), has been well documented in pulmonary EC; however, few data exist regarding the relative activity of ACE in the airway vasculature. Therefore, we measured ACE activity in cultured EC from the sheep bronchial artery and bronchial mucosa (microvascular) and compared it with pulmonary artery EC. The baseline level of total ACE activity (cellular plus secreted) was significantly greater in bronchial microvascular EC (1.24 ± 0.24 mU/106 cells) compared with bronchial artery EC (0.59 ± 0.15 mU/106 cells; P < 0.05) and comparable to pulmonary artery EC (1.12 ± 0.14 mU/106 cells; P > 0.05). Measured ACE activity secreted into culture medium for each cell type was 64–74% of total activity and did not differ among the three EC types (P = 0.17). Hydrocortisone (10 µg/ml; 48–72 h) treatment resulted in a significant increase in ACE activity in bronchial EC. Likewise, TNF-{alpha} (0.1 ng/ml) treatment markedly increased ACE activity in all cell lysates (P < 0.05). We confirmed the importance of ACE activity in vivo since, at the highest dose of bradykinin studied (10–8 M), bronchial artery pressure at constant flow showed a greater decrease after captopril treatment (36% before vs. 60% after; P = 0.05). These results demonstrate high ACE expression of the bronchial microvasculature and suggest an important regulatory role for ACE in the metabolism of kinin peptides known to contribute to airway pathology.

bronchial endothelial cells; captopril; hydrocortisone; tumor necrosis factor-{alpha}


Address for reprint requests and other correspondence: E. M. Wagner, Johns Hopkins Asthma and Allergy Center, Division of Pulmonary and Critical Care Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 (E-mail: wagnerem{at}jhmi.edu).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.